SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IGT ((VSE:IGT) Blockbuster Anti-Cancer Test Results !!!
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Solid Play who wrote ()7/31/1997 8:11:00 PM
From: jean paul sauvT   of 94
 
To all:

National Research Council grant awarded

IGT Pharma Inc IGT
Shares issued 6,653,332 Jul 30 close $1.21
Thu 31 Jul 97 News Release
Mr Bruce Schmidt reports
IGT has recently received a grant from the National Research Council of
Canada (NRC) under its Industrial Research Assistance Program (IRAP).
The $136,500 grant is provided to further the commercial development of
IGT's innovative synthetic route to Etoposide and its analogues. Etoposide
(VP-16) is one of the largest existing generic anti-cancer drugs used for
the treatment of solid tumors and used in various standard combination
therapies. Specifically, the key objective of this phase of the project is
the engineered scale-up of the patent pending commercial synthetic
production process to Etoposide. IGT recently announced the filing of a
patent application for the production methodology for a totally synthetic
version of Etoposide. This novel process will provide significant financial
leverage due to the fact that only common and inexpensive starting
materials will be required and thereby completely eliminating the need for
plant material.
The second objective is the further development of IGT's Etoposide
derivatives which provide a template for development of new drugs that have
exhibited greater anti-tumor activity and selectivity than current
naturally derived drugs in use. Although Etoposide is currently a
blockbuster generic drug, IGT's investigation of analogs has produced
versions that appear, in preliminary evaluations, in many respects to be
superior to Etoposide itself. This highly active drug potential hopes to
address the problem of cancers that develop multi-drug resistance. The
finalization of continuing pre-clinical investigations at the B.C. Cancer
Agency will confirm the potential of this compound thus allowing for the
development of a full pre-clinical and clinical program.
(c) Copyright 1997 Canjex Publishing Ltd. canada-stockwatch.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News